RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.81 -0.11 (11.96%)
Previous Close $0.92    52 Week High $16.54 
Open $0.89    52 Week Low $8.10 
Day High $0.90    P/E N/A 
Day Low $0.78    EPS $0.00 
Volume 188,975       

REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.81 -0.11 (11.96%)
Previous Close $0.92    52 Week High $16.54 
Open $0.89    52 Week Low $8.10 
Day High $0.90    P/E N/A 
Day Low $0.78    EPS $0.00 
Volume 188,975